Absence of prognostic significance of p21WAF1/CIP1 protein expression in non-small cell lung cancer

Acta Oncologica

Volumn 44, Issue 1, 2005, Pages 75-79

  Dworakowska, Dorota ^a   Jassem, Ewa ^a   Jassem, Jacek ^a   Boltze, Carsten ^b   Wiedorn, Klaus Hermann ^c   Dworakowski, Rafal ^a   Skokowski, Jan ^a   Jaśkiewicz, Kazimierz ^a   Czȩstochowska, Eugenia ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c Katharinenhospital ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 13844275550     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510007422     Document Type: Article

References (25)

1. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
2. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
3. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-7.
4. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-44.
5. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997;277:831-4.
6. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996;10:1945-52.
7. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1):association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002;179:1-14.
8. Marx J. New link found between p53 and DNA repair. Science 1994;266:1321-2.
9. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D, Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
10. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, et al. p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996;12:1319-24.
11. Hayashi H, Miyamoto H, Ito T, Kameda Y, Nakamura N, Kubota Y, Kitamura H. Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am J Pathol 1997;151:461-70.
12. Vonlanthen S, Heighway J, Kappeler A, Altermatt HJ, Borner MM, Betticher DC. p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol 2000;16:951-7.
13. Aikawa H, Sato M, Fujimura S, Takahashi H, Endo C, Sakurada A, et al. Mdm2 expression is associated with progress of disease and WAF1 expression in resected lung cancer. Int J Mol Med 2000;5:631-3.
14. Xue Q, Sano T, Kashiwabara K, Oyama T, Nakajima T:Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung. Jpn J Cancer Res 2001;92:285-92.
15. Takeshima Y, Yamasaki M, Nishisaka T, Kitaguchi S, Inai K:p21WAF1/CIP1 expression in primary lung adenocarcinomas: Heterogeneous expression in tumor tissues and correlation with p53 expression and proliferative activities. Carcinogenesis 1998;19:1755-61.
16. Groeger AM, Caputi M, Esposito V, Baldi A, Rossiello R, Santini D, et al. Expression of p21 in non small cell lung cancer relationship with PCNA. Anticancer Res 2000;20:3301-5.
17. Akita K, Inagaki H, Sato S, Niimi T, Maeda H, Ninomiya S, et al. p185(HER-2/neu) and p21(CIP1/WAF1) expression in primary tumors and lymph node metastases in non-small cell lung cancer. Jpn J Cancer Res 2002;93:1007-11.
18. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997;3:1831-5.
19. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer:relationship to survival. Am J Respir Cell Mol Biol 1998;18:213-7.
20. Bennett WP, el-Deiry WS, Rush WL, Guinee DG, Freedman AN, Caporaso NE, et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 1998;4:1499-506.
21. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-71.
22. Esposito V, Baldi A, Tonini G, Vincenzi B, Santini M, Ambrogi V, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004;57:58-63.
23. Dworakowska D, Jassem E, Jassem J, Wiedorn KH, Boltze C, Karolinski A, et al. Prognostic relevance of altered pRb and p53 protein expression in surgically treated non-small cell lung cancer patients. Oncology 2004;67:60-6.
24. World Health Organization. Histological typing of lung tumors. 2nd ed. Geneva: WHO; 1981.
25. International Union Against Cancer. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997. p. 93-7.